Key facts
- This page summarizes Neil Kumar's Form 4 filing for Maze Therapeutics, Inc. (MAZE).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 31 Mar 2026, 16:13.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on April 27, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.